Equities analysts predict that Hologic, Inc. (NASDAQ:HOLX) will report $779.91 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Hologic’s earnings, with the highest sales estimate coming in at $783.70 million and the lowest estimate coming in at $777.70 million. Hologic posted sales of $715.40 million during the same quarter last year, which suggests a positive year over year growth rate of 9%. The business is expected to report its next quarterly earnings results on Wednesday, May 9th.
According to Zacks, analysts expect that Hologic will report full-year sales of $779.91 million for the current fiscal year, with estimates ranging from $3.23 billion to $3.28 billion. For the next year, analysts expect that the firm will post sales of $3.40 billion per share, with estimates ranging from $3.37 billion to $3.43 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Hologic.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The firm had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. During the same period last year, the business earned $0.52 EPS. Hologic’s revenue for the quarter was up 7.7% compared to the same quarter last year.
Several equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Needham & Company LLC reiterated a “buy” rating and set a $50.00 price target on shares of Hologic in a research note on Friday, February 9th. Deutsche Bank lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research note on Friday, January 19th. Canaccord Genuity reiterated a “buy” rating and set a $48.00 price target on shares of Hologic in a research note on Friday, February 9th. Finally, Evercore ISI assumed coverage on shares of Hologic in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $48.00.
Shares of Hologic (NASDAQ:HOLX) opened at $38.46 on Friday. Hologic has a one year low of $35.33 and a one year high of $46.80. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25. The company has a market cap of $10,629.78, a price-to-earnings ratio of 10.15, a P/E/G ratio of 1.73 and a beta of 0.84.
In other Hologic news, Director Charles J. Dockendorff acquired 13,000 shares of the stock in a transaction on Thursday, March 15th. The shares were bought at an average cost of $38.80 per share, with a total value of $504,400.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Namal Nawana acquired 6,600 shares of the stock in a transaction on Tuesday, February 13th. The shares were acquired at an average cost of $37.88 per share, for a total transaction of $250,008.00. Following the completion of the transaction, the director now directly owns 6,954 shares in the company, valued at approximately $263,417.52. The disclosure for this purchase can be found here. Company insiders own 0.79% of the company’s stock.
A number of institutional investors have recently modified their holdings of HOLX. Parnassus Investments CA boosted its holdings in shares of Hologic by 88.6% in the fourth quarter. Parnassus Investments CA now owns 14,240,875 shares of the medical equipment provider’s stock valued at $608,797,000 after acquiring an additional 6,689,454 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Hologic by 5.8% in the fourth quarter. Victory Capital Management Inc. now owns 6,199,017 shares of the medical equipment provider’s stock valued at $265,008,000 after acquiring an additional 342,239 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in shares of Hologic by 28.1% in the fourth quarter. Two Sigma Advisers LP now owns 2,828,311 shares of the medical equipment provider’s stock valued at $120,910,000 after acquiring an additional 620,761 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Hologic by 5.7% in the third quarter. Dimensional Fund Advisors LP now owns 1,969,026 shares of the medical equipment provider’s stock valued at $72,243,000 after acquiring an additional 105,360 shares in the last quarter. Finally, Guggenheim Capital LLC boosted its holdings in shares of Hologic by 46.0% in the fourth quarter. Guggenheim Capital LLC now owns 1,662,053 shares of the medical equipment provider’s stock valued at $71,053,000 after acquiring an additional 523,654 shares in the last quarter. 97.59% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/779-91-million-in-sales-expected-for-hologic-inc-holx-this-quarter-2.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Get a free copy of the Zacks research report on Hologic (HOLX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.